

ABSTRACT

5 This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H_3 receptor antagonist / m_2 muscarinic antagonist, or a combination of a histamine H_3 receptor antagonist and a m_2 muscarinic antagonist.